Swiss National Bank
AKRO

Swiss National Bank’s Akero Therapeutics AKRO Stock Holding History

Swiss National Bank’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-108,100
Closed -$5.13M – 2314
2025
Q3 		$5.13M Buy
108,100
+1,700
+2% +$82.3K ﹤0.01% 1315
2025
Q2 		$5.68M Buy
106,400
+11,700
+12% +$532K ﹤0.01% 1218
2025
Q1 		$3.83M Sell
94,700
-900
-0.9% -$38.1K ﹤0.01% 1416
2024
Q4 		$2.66M Buy
95,600
+1,100
+1% +$33.3K ﹤0.01% 1693
2024
Q3 		$2.71M Sell
94,500
-7,500
-7% -$196K ﹤0.01% 1684
2024
Q2 		$2.39M Sell
102,000
-3,000
-3% -$64.2K ﹤0.01% 1718
2024
Q1 		$2.65M Buy
105,000
+17,400
+20% +$418K ﹤0.01% 1685
2023
Q4 		$2.05M Sell
87,600
-9,700
-10% -$191K ﹤0.01% 1816
2023
Q3 		$4.92M Buy
97,300
+1,000
+1% +$46.6K ﹤0.01% 1290
2023
Q2 		$4.5M Buy
96,300
+30,700
+47% +$1.41M ﹤0.01% 1373
2023
Q1 		$2.51M Sell
65,600
-5,400
-8% -$241K ﹤0.01% 1696
2022
Q4 		$3.89M Buy
71,000
+1,800
+3% +$77.1K ﹤0.01% 1465
2022
Q3 		$2.36M Buy
69,200
+19,800
+40% +$303K ﹤0.01% 1753
2022
Q2 		$467K Buy
49,400
+12,300
+33% +$128K ﹤0.01% 2624
2022
Q1 		$526K Buy
37,100
+2,700
+8% +$47.3K ﹤0.01% 2596
2021
Q4 		$728K Hold
34,400
– – ﹤0.01% 2575
2021
Q3 		$769K Hold
34,400
– – ﹤0.01% 2499
2021
Q2 		$853K Sell
34,400
-900
-3% -$25.3K ﹤0.01% 2534
2021
Q1 		$1.02M Hold
35,300
– – ﹤0.01% 2338
2020
Q4 		$911K Buy
35,300
+700
+2% +$19.5K ﹤0.01% 2338
2020
Q3 		$1.06M Buy
34,600
+12,200
+54% +$426K ﹤0.01% 2062
2020
Q2 		$558K Buy
+22,400
New +$512K ﹤0.01% 2357

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Swiss National Bank's AKRO Position: Q4 2025 in Review

Swiss National Bank sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 108,100 shares — an estimated $5.13M sold.

Swiss National Bank first reported a position in AKRO in Q2 2020 and held it in 22 quarters. The position peaked at $5.68M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Swiss National Bank reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Swiss National Bank sold 108,100 Akero Therapeutics shares in Q4 2025, an estimated $5.13M.
  • Swiss National Bank first reported a position in Akero Therapeutics in Q2 2020 and held it in 22 quarters.
  • Swiss National Bank's Akero Therapeutics position peaked at $5.68M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Swiss National Bank's 13F filing for Q4 2025, filed 12 Feb 2026.